MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Pay-per-Click New!
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

Peptides for Prevention of Pathological Calcification

WORLDiscoveries™
A number of select phospho-peptides that are derived from the crystal-inhibiting protein osteopontin and that have a distinct set of structural criteria.

Full description

Key Areas: Kidney Stones; Ectopic Calcification

DESCRIPTION OF THE INVENTION: The present invention consists in a number of select phospho-peptides that are derived from the crystal-inhibiting protein osteopontin and that have a distinct set of structural criteria. In vitro proof of principle data demonstrate that such therapeutic peptides bind to specific faces in calcium oxalate monohydrate crystals (the nuclei of kidney stones), and prevent growth perpendicular to those faces. As a result, these proprietary peptides have the potential to be used in the treatment and prevention of kidney stone formation and growth.  

BACKGROUND: Kidney stones represent a widespread, painful medical problem that is estimated to affect approximately 10% of the population with up to 60% of patients suffering a recurrent episode. Kidney stones are a significant cause of morbidity leading to time away from work and frequently necessitate surgical intervention with an estimated burden to health care and socioeconomic expenditures of $2 billion annually in the US. The incidence of disease is believed to have increased over the last few decades, particularly among Caucasian males in the United States and other predominantly Caucasian-populated nations.

The most common type of kidney stone, or renal stone, is idiopathic in origin and generally calcareous. In contrast to the normal biomineralization of bones and teeth, the calcium oxalate biomineralization which is believed to cause renal stones contributes significantly to the cost of health care in the United States.

It is believed that crystallization within the urinary tract occurs on an ongoing basis, with the formation of small crystals providing the usual excretory function for eliminating calcareous stone salts. It is when such crystallization is not restricted to the urinary tract that the formation of unwanted crystalline stones in the kidney occurs.

At present there is no effective medical therapy to prevent or treat kidney stones and surgical methods often result in recurrence of kidney stone formation.

POTENTIAL ADVANTAGES/USES: The present invention addressed the need for a simple, noninvasive, outpatient approach for inhibiting the growth of kidney stones and for discouraging recurrence on a maintenance basis. The advantages of this technology are that it mimics a natural process of crystal inhibition and that it involves a set of small molecules. 

Reference Number: UWO-AG-035 

Development status

Preclinical

Patent information

PCT stage

Type of business relationship sought

Collaborative/Licensing Agreement 

Licensing contact

Dr. Ting Ling
Business Development Manager, Life Sci
WORLDiscoveries™

Contact directly

Company details

WORLDiscoveries™

WORLDiscoveries™ is the business development arm of London’s extensive research network and the bridge between local invention and global industry.

View profile

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Related items

Related categories

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
Anglonordic VII
Press releases: Pharmalicensing current industry press releases.

© Copyright 1998-2010 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us